
|Articles|January 27, 2021
Supplements and Featured Publications
- The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
Advertisement
This publication is sponsored by Novartis AG.
This Clinical Practice Brief provides an overview of the genetic cardiovascular risk biomarker lipoprotein a (Lp[a]), as well as its importance as an independent risk factor for cardiovascular disease, the prevalence of elevated Lp(a) levels among the global population, and recommendations for lipid management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
2
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
3
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
4
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML
5














































